| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;99:3043-3049.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Tissue Inhibition of Angiotensin-Converting Enzyme Activity Stimulates Angiogenesis In Vivo
From the Departments of Medicine (Vascular Medicine) and Biomedical Research, St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Mass.
Correspondence to Jeffrey M. Isner, MD, St Elizabeth's Medical Center, 736 Cambridge St, Boston, MA 02135. E-mail jisner{at}opal.tufts.edu
Background—Endothelial cells (ECs) represent the critical cellular element responsible for postnatal angiogenesis. Because ACE inhibitors may favorably affect endothelial function, we investigated the hypothesis that administration of the ACE inhibitor quinaprilat could enhance angiogenesis in vivo.
Methods and Results—Ten days after resection of 1 femoral artery, New Zealand White (NZW) rabbits were randomly assigned to receive recombinant human vascular endothelial growth factor (rhVEGF) administered as a single intra-arterial injection (n=6), quinaprilat (n=8) or captopril (n=7) administered as a daily subcutaneous injection, or no treatment (controls, n=6). Angiogenesis was monitored in vivo by measurement of blood pressure, vasoreactivity, and resistance in ischemic versus normal limbs at day 10 (D10) and D40; angiographic studies to identify sites of neovascularization were performed at D10 and D40, and morphometric analysis of capillary density in the ischemic limb was performed at necropsy (D40). Both functional and morphological outcomes documented augmented angiogenesis in quinaprilat-treated rabbits similar to that observed for rhVEGF and superior to that observed with either captopril or no drug (controls). Residual ACE activity was equivalent for the captopril and quinaprilat groups in plasma (42.54±0.03% versus 41.53±0.02%, P=NS) but not in tissue, where quinaprilat lowered ACE activity significantly (P<0.01) compared with captopril (13% versus 61%).
Conclusions—ACE inhibition with quinaprilat promotes angiogenesis in a rabbit model of hindlimb ischemia. Thus, nonsulfhydryl ACE inhibitors with high tissue affinity may be potentially useful for therapeutic angiogenesis in ischemic tissues. Moreover, previous evidence that ACE inhibition benefits patients with myocardial ischemia may be due in part to augmented collateral development.
Key Words: angiogenesis • angiotensin • growth substances • ischemia
This article has been cited by other articles:
 |
|
 |
|
  E. Habouzit, H. Richard, H. Sanchez, N. Koulmann, B. Serrurier, R. Monnet, R. Ventura-Clapier, and X. Bigard Decreased muscle ACE activity enhances functional response to endurance training in rats, without change in muscle oxidative capacity or contractile phenotype J Appl Physiol, July 1, 2009; 107(1): 346 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mouquet, F. Cuilleret, S. Susen, K. Sautiere, P. Marboeuf, P. V. Ennezat, E. McFadden, P. Pigny, F. Richard, B. Hennache, et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1 Eur. Heart J., April 1, 2009; 30(7): 840 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sanchez de Miguel, S. Neysari, S. Jakob, M. Petrimpol, N. Butz, A. Banfi, C. E. Zaugg, R. Humar, and E. J. Battegay B2-kinin receptor plays a key role in B1-, angiotensin converting enzyme inhibitor-, and vascular endothelial growth factor-stimulated in vitro angiogenesis in the hypoxic mouse heart Cardiovasc Res, October 1, 2008; 80(1): 106 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. You, C. Cochain, C. Loinard, J. Vilar, B. Mees, M. Duriez, B. I. Levy, and J.-S. Silvestre Combination of the Angiotensin-Converting Enzyme Inhibitor Perindopril and the Diuretic Indapamide Activate Postnatal Vasculogenesis in Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. You, C. Cochain, C. Loinard, J. Vilar, B. Mees, M. Duriez, B. I. Levy, and J.-S. Silvestre Hypertension Impairs Postnatal Vasculogenesis: Role of Antihypertensive Agents Hypertension, June 1, 2008; 51(6): 1537 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Li, T. Kondo, Y. Numaguchi, K. Kobayashi, M. Aoki, N. Inoue, K. Okumura, and T. Murohara Role of Bradykinin, Nitric Oxide, and Angiotensin II Type 2 Receptor in Imidapril-Induced Angiogenesis Hypertension, February 1, 2008; 51(2): 252 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Velasquez-Castano and W. R. Taylor Angiotensin II and New Vessel Formation: Aiming for the Right Oxidative Window Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 4 - 5. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nagai, Y. Oike, K. Izumi-Nagai, T. Koto, S. Satofuka, H. Shinoda, K. Noda, Y. Ozawa, M. Inoue, K. Tsubota, et al. Suppression of Choroidal Neovascularization by Inhibiting Angiotensin-Converting Enzyme: Minimal Role of Bradykinin Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2321 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Miller, L. E. Norton, M. P. Murphy, M. C. Dalsing, and J. L. Unthank The role of the renin-angiotensin system and oxidative stress in spontaneously hypertensive rat mesenteric collateral growth impairment Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2523 - H2531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sano, K. Hosokawa, H. Kidoya, and N. Takakura Negative Regulation of VEGF-Induced Vascular Leakage by Blockade of Angiotensin II Type 1 Receptor Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2673 - 2680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Feihl, L. Liaudet, B. Waeber, and B. I. Levy Hypertension: A Disease of the Microcirculation? Hypertension, December 1, 2006; 48(6): 1012 - 1017. [Full Text] [PDF]
|
|
|
|
|
|
S. Donnini, R. Solito, A. Giachetti, H. J. Granger, M. Ziche, and L. Morbidelli Fibroblast Growth Factor-2 Mediates Angiotensin-Converting Enzyme Inhibitor-Induced Angiogenesis in Coronary Endothelium J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 515 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Petersen, D. H. Munzenmaier, and A. S. Greene Angiotensin II infusion restores stimulated angiogenesis in the skeletal muscle of rats on a high-salt diet Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H114 - H120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Ahimastos, A. Lawler, C. M. Reid, P. A. Blombery, and B. A. Kingwell Brief Communication: Ramipril Markedly Improves Walking Ability in Patients with Peripheral Arterial Disease: A Randomized Trial Ann Intern Med, May 2, 2006; 144(9): 660 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Waeckel, J. Bignon, J.-M. Liu, D. Markovits, T. G. Ebrahimian, J. Vilar, B. Mees, O. Blanc-Brude, V. Barateau, S. Le ricousse-Roussanne, et al. Tetrapeptide AcSDKP Induces Postischemic Neovascularization Through Monocyte Chemoattractant Protein-1 Signaling Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 773 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Lazar Role of Angiotensin-Converting Enzyme Inhibitors in the Coronary Artery Bypass Patient Ann. Thorac. Surg., March 1, 2005; 79(3): 1081 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Ebrahimian, R. Tamarat, M. Clergue, M. Duriez, B. I. Levy, and J.-S. Silvestre Dual Effect of Angiotensin-Converting Enzyme Inhibition on Angiogenesis in Type 1 Diabetic Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 65 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Unthank, K. M. Sheridan, and M. C. Dalsing Collateral Growth in the Peripheral Circulation: A Review Vascular and Endovascular Surgery, July 1, 2004; 38(4): 291 - 313. [Abstract] [PDF]
|
|
|
|
|
|
R. H.P. Hilgers, P. M.H. Schiffers, W. M. Aartsen, G. E. Fazzi, J. F.M. Smits, and J. G.R. De Mey Tissue Angiotensin-Converting Enzyme in Imposed and Physiological Flow-Related Arterial Remodeling in Mice Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 892 - 897. [Abstract] [Full Text]
|
|
|
|
|
|
T. Ichiki Role of Renin Angiotensin System in Angiogenesis: It Is Still Elusive Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 622 - 624. [Full Text] [PDF]
|
|
|
|
|
|
H. Toko, Y. Zou, T. Minamino, M. Sakamoto, M. Sano, M. Harada, T. Nagai, T. Sugaya, F. Terasaki, Y. Kitaura, et al. Angiotensin II Type 1a Receptor Is Involved in Cell Infiltration, Cytokine Production, and Neovascularization in Infarcted Myocardium Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 664 - 670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. I. Levy Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin-Angiotensin System Circulation, January 6, 2004; 109(1): 8 - 13. [Full Text] [PDF]
|
|
|
|
|
|
N. P. Fam, S. Verma, M. Kutryk, and D. J. Stewart Clinician Guide to Angiogenesis Circulation, November 25, 2003; 108(21): 2613 - 2618. [Full Text] [PDF]
|
|
|
|
 |
|
 A. T Hirsch and D. Duprez The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease Vascular Medicine, November 1, 2003; 8(4): 273 - 278. [Abstract] [PDF]
|
|
|
|
 |
|
 T. WALTHER, A. MENRAD, H.-D. ORZECHOWSKI, G. SIEMEISTER, M. PAUL, and M. SCHIRNER Differential regulation of in vivo angiogenesis by angiotensin II receptors FASEB J, November 1, 2003; 17(14): 2061 - 2067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Srivastava, R. L. Terjung, and H. T. Yang Basic fibroblast growth factor increases collateral blood flow in spontaneously hypertensive rats Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1190 - H1197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-i. Miura, Y. Matsuo, and K. Saku Transactivation of KDR/Flk-1 by the B2 Receptor Induces Tube Formation in Human Coronary Endothelial Cells Hypertension, May 1, 2003; 41(5): 1118 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Liu, F. Lawrence, M. Kovacevic, J. Bignon, E. Papadimitriou, J.-Y. Lallemand, P. Katsoris, P. Potier, Y. Fromes, and J. Wdzieczak-Bakala The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo Blood, April 15, 2003; 101(8): 3014 - 3020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-S. Silvestre, N. Kamsu-Kom, M. Clergue, M. Duriez, and B. I. Levy Very-Low-Dose Combination of the Angiotensin-Converting Enzyme Inhibitor Perindopril and the Diuretic Indapamide Induces an Early and Sustained Increase in Neovascularization in Rat Ischemic Legs J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1038 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Loufrani, Z. Li, B. I. Levy, D. Paulin, and D. Henrion Excessive Microvascular Adaptation to Changes in Blood Flow in Mice Lacking Gene Encoding for Desmin Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1579 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Katada, M. Muramatsu, I. Hayashi, M. Tsutsumi, Y. Konishi, and M. Majima Significance of Vascular Endothelial Cell Growth Factor Up-Regulation Mediated via a Chymase-Angiotensin-Dependent Pathway during Angiogenesis in Hamster Sponge Granulomas J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 949 - 956. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Celerier, A. Cruz, N. Lamande, J.-M. Gasc, and P. Corvol Angiotensinogen and Its Cleaved Derivatives Inhibit Angiogenesis Hypertension, February 1, 2002; 39(2): 224 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takeshita, H. Tomiyama, N. Yokoyama, Y. Kawamura, T. Furukawa, Y. Ishigai, T. Shibano, T. Isshiki, and T. Sato Angiotensin-converting enzyme inhibition improves defective angiogenesis in the ischemic limb of spontaneously hypertensive rats Cardiovasc Res, November 1, 2001; 52(2): 314 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Amaral, P. E. Papanek, and A. S. Greene Angiotensin II and VEGF are involved in angiogenesis induced by short-term exercise training Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1163 - H1169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.I. Levy, G. Ambrosio, A.R. Pries, and H.A.J. Struijker-Boudier Microcirculation in Hypertension: A New Target for Treatment? Circulation, August 1, 2001; 104(6): 735 - 740. [Full Text] [PDF]
|
|
|
|
|
|
C. Emanueli, M. B. Salis, T. Stacca, L. Gaspa, J. Chao, L. Chao, A. Piana, and P. Madeddu Rescue of Impaired Angiogenesis in Spontaneously Hypertensive Rats by Intramuscular Human Tissue Kallikrein Gene Transfer Hypertension, July 1, 2001; 38(1): 136 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-p. Sun, B.-q. Zhu, A. E. M. Browne, S. Pulukurthy, T. M. Chou, K. Sudhir, S. A. Glantz, P. C. Deedwania, K. Chatterjee, and W. W. Parmley Comparative Effects of ACE Inhibitors and an Angiotensin Receptor Blocker on Atherosclerosis and Vascular Function Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 175 - 181. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Yoshiji, S. Kuriyama, M. Kawata, J. Yoshii, Y. Ikenaka, R. Noguchi, T. Nakatani, H. Tsujinoue, and H. Fukui The Angiotensin-I-converting Enzyme Inhibitor Perindopril Suppresses Tumor Growth and Angiogenesis: Possible Role of the Vascular Endothelial Growth Factor Clin. Cancer Res., April 1, 2001; 7(4): 1073 - 1078. [Abstract] [Full Text]
|
|
|
|
|
|
O. Saijonmaa, T. Nyman, R. Kosonen, and F. Fyhrquist Upregulation of angiotensin-converting enzyme by vascular endothelial growth factor Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H885 - H891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Amaral, R. J. Roman, and A. S. Greene Renin Gene Transfer Restores Angiogenesis and Vascular Endothelial Growth Factor Expression in Dahl S Rats Hypertension, February 1, 2001; 37(2): 386 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Emanueli, A. Minasi, A. Zacheo, J. Chao, L. Chao, M. B. Salis, S. Straino, M. G. Tozzi, R. Smith, L. Gaspa, et al. Local Delivery of Human Tissue Kallikrein Gene Accelerates Spontaneous Angiogenesis in Mouse Model of Hindlimb Ischemia Circulation, January 2, 2001; 103(1): 125 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. O'Keefe, M. Wetzel, R. R. Moe, K. Brosnahan, and C. J. Lavie Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J. Am. Coll. Cardiol., January 1, 2001; 37(1): 1 - 8. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Emanueli, A. Zacheo, A. Minasi, J. Chao, L. Chao, M. B. Salis, T. Stacca, S. Straino, M. C. Capogrossi, and P. Madeddu Adenovirus-Mediated Human Tissue Kallikrein Gene Delivery Induces Angiogenesis in Normoperfused Skeletal Muscle Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20(11): 2379 - 2385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Goldstein Tissue Inhibition of Angiotensin-Converting Enzyme Activity Stimulates Angiogenesis In Vivo: A Potential Downside Circulation, August 8, 2000; 102 (6): e39 - e39. [Full Text] [PDF]
|
|
|
|
|
|
T. P. Gavin, D. A. Spector, H. Wagner, E. C. Breen, and P. D. Wagner Effect of captopril on skeletal muscle angiogenic growth factor responses to exercise J Appl Physiol, May 1, 2000; 88(5): 1690 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Busse and I. Fleming A critical look at cardiovascular translational research Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H1655 - H1660. [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Silvestre, S. Bergaya, R. Tamarat, M. Duriez, C. M. Boulanger, and B. I. Levy Proangiogenic Effect of Angiotensin-Converting Enzyme Inhibition Is Mediated by the Bradykinin B2 Receptor Pathway Circ. Res., October 12, 2001; 89(8): 678 - 683. [Abstract] [Full Text] [PDF]
|
|